Correlation Between Madrigal Pharmaceuticals and Elevai Labs,

Can any of the company-specific risk be diversified away by investing in both Madrigal Pharmaceuticals and Elevai Labs, at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Madrigal Pharmaceuticals and Elevai Labs, into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Madrigal Pharmaceuticals and Elevai Labs, Common, you can compare the effects of market volatilities on Madrigal Pharmaceuticals and Elevai Labs, and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Madrigal Pharmaceuticals with a short position of Elevai Labs,. Check out your portfolio center. Please also check ongoing floating volatility patterns of Madrigal Pharmaceuticals and Elevai Labs,.

Diversification Opportunities for Madrigal Pharmaceuticals and Elevai Labs,

-0.95

Correlation Coefficient

Madrigal Pharmaceuticals  Elevai Labs,

Pay attention - limited upside

The 3 months correlation between Madrigal and Elevai is -0.95. Overlapping area represents the amount of risk that can be diversified away by holding Madrigal Pharmaceuticals and Elevai Labs, Common in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Elevai Labs, Common and Madrigal Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Madrigal Pharmaceuticals are associated (or correlated) with Elevai Labs,. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Elevai Labs, Common has no effect on the direction of Madrigal Pharmaceuticals i.e., Madrigal Pharmaceuticals and Elevai Labs, go up and down completely randomly.

Pair Corralation between Madrigal Pharmaceuticals and Elevai Labs,

Given the investment horizon of 90 days Madrigal Pharmaceuticals is expected to generate 13.8 times less return on investment than Elevai Labs,. But when comparing it to its historical volatility, Madrigal Pharmaceuticals is 4.06 times less risky than Elevai Labs,. It trades about 0.03 of its potential returns per unit of risk. Elevai Labs, Common is currently generating about 0.1 of returns per unit of risk over similar time horizon. If you would invest  210.00  in Elevai Labs, Common on October 9, 2024 and sell it today you would earn a total of  22.00  from holding Elevai Labs, Common or generate 10.48% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Significant
Accuracy	95.0%
Values	Daily Returns

Madrigal Pharmaceuticals  vs.  Elevai Labs, Common

Madrigal Pharmaceuticals

Risk-Adjusted Performance

13 of 100

Good

Compared to the overall equity markets, risk-adjusted returns on investments in Madrigal Pharmaceuticals are ranked lower than 13 (%) of all global equities and portfolios over the last 90 days. Despite quite uncertain technical and fundamental indicators, Madrigal Pharmaceuticals disclosed solid returns over the last few months and may actually be approaching a breakup point.

Elevai Labs, Common

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Elevai Labs, Common has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in February 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

Pair Trading with Madrigal Pharmaceuticals and Elevai Labs,

The main advantage of trading using opposite Madrigal Pharmaceuticals and Elevai Labs, positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Madrigal Pharmaceuticals position performs unexpectedly, Elevai Labs, can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Elevai Labs, will offset losses from the drop in Elevai Labs,'s long position.

The idea behind Madrigal Pharmaceuticals and Elevai Labs, Common pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.